Photomanipulation of antibiotic susceptibility and biofilm formation of Escherichia coli heterologously expressing photoactivated adenylyl cyclase

Yasukawa, Hiro; Konno, Norifumi; Haneda, Yukari; Yamamori, Baku; Iseki, Mineo; Shibusawa, Mami; Ono, Yasushi; Kodaira, Ken-Ichi; Funada, Hisashi; Watanabe, Masakatsu

doi:10.2323/jgam.58.183

Cited by 8 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were obtained in the study of Yasukawa et al (Yasukawa et al, 2012). After being pre-treated with aBL (470 nm), E. coli cells expressing BsPAC became more susceptible to fosfomycin, nalidixic acid, and streptomycin than the cells incubated in the dark.…”

Section: Synergism Of Antimicrobial Blue Light With Other Agentssupporting

confidence: 92%

Antimicrobial blue light inactivation of pathogenic microbes: State of the art

Wang

et al. 2017

Drug Resistance Updates

223

192

View full text Add to dashboard Cite

As an innovative non-antibiotic approach, antimicrobial blue light in the spectrum of 400–470 nm has demonstrated its intrinsic antimicrobial properties resulting from the presence of endogenous photosensitizing chromophores in pathogenic microbes and, subsequently, its promise as a counteracter of antibiotic resistance. Since we published our last review of antimicrobial blue light in 2012, there have been a substantial number of new studies reported in this area. Here we provide an updated overview of the findings from the new studies over the past 5 years, including the efficacy of antimicrobial blue light inactivation of different microbes, its mechanism of action, synergism of antimicrobial blue light with other angents, its effect on host cells and tissues, the potential development of resistance to antimicrobial blue light by microbes, and a novel interstitial delivery approach of antimicrobial blue light. The potential new applications of antimicrobial blue light are also discussed.

show abstract

Section: Synergism Of Antimicrobial Blue Light With Other Agentssupporting

confidence: 92%

Antimicrobial blue light inactivation of pathogenic microbes: State of the art

Wang

et al. 2017

Drug Resistance Updates

223

192

View full text Add to dashboard Cite

show abstract

“…So far, bPAC has been successfully utilized to study cAMP-dependent signaling in various cell types and whole animals. Elevation of the cellular cAMP level increased antibiotic susceptibility and the level of biofilm formation in E. coli . cAMP-related behavioral responses were studied using bPAC even in whole animals like zebrafish .…”

mentioning

confidence: 99%

“…Elevation of the cellular cAMP level increased antibiotic susceptibility and the level of biofilm formation in E. coli. 9 cAMP-related behavioral responses were studied using bPAC even in whole animals like zebrafish. 10 The combination with conventional pharmaceutical cAMP stimulants allowed the resolution of the physiologically different functions of the cAMP effectors PKA and EPAC in the Drosophila renal system.…”

mentioning

confidence: 99%

Key Residues for the Light Regulation of the Blue Light-Activated Adenylyl Cyclase from Beggiatoa sp.

et al. 2014

View full text Add to dashboard Cite

Photoactivated adenylyl cyclases are powerful tools for optogenetics and for investigating signal transduction mechanisms in biological photoreceptors. Because of its large increase in enzyme activity in the light, the BLUF (blue light sensor using flavin adenine dinucleotide)-activated adenylyl cyclase (bPAC) from Beggiatoa sp. is a highly attractive model system for studying BLUF domain signaling. In this report, we studied the influence of site-directed mutations within the BLUF domain on the light regulation of the cyclase domain and determined key elements for signal transduction and color tuning. Photoactivation of the cyclase domain is accomplished via strand β5 of the BLUF domain and involves the formation of helical structures in the cyclase domain as assigned by vibrational spectroscopy. In agreement with earlier studies, we observed severely impaired signaling in mutations directly on strand β5 as well as in mutations affecting the hydrogen bond network around the flavin. Moreover, we identified a bPAC mutant with red-shifted absorbance and a decreased dark activity that is highly valuable for long-term optogenetic experiments. Additionally, we discovered a mutant that forms a stable neutral flavin semiquinone radical in the BLUF domain and surprisingly exhibits an inversion of light activation.

show abstract

“…Some pre-clinical studies also showed that no aBL-resistance development was observed by microbes after up to 10 cycles successive sub-lethal aBL inactivation [17,18,21]. In addition, aBL was also found to have synergistic effect with other antimicrobials, such as medicinal plants and their extracts [22–25], antibiotics [26,27], and disinfectants [28–30]. In contrast to pre-clinical studies, very few clinical studies have been reported so far.…”

Section: Recent Patents On Light-based Anti-infective Approachesmentioning

confidence: 99%

Recent Patents on Light-Based Anti-Infective Approaches

Ahmed

Fang

Lü

et al. 2018

PRI

View full text Add to dashboard Cite

Background Antibiotic resistance is one of the most serious health threats to modern medicine. The lack of potent antibiotics puts us at a disadvantage in the fight against infectious diseases, especially those caused by antibiotic-resistant microbial strains. To this end, an urgent need to search for alternative antimicrobial approaches has arisen. In the last decade, light-based therapy has made significant strides in this fight to combat antibiotic resistance among various microbial strains. This method includes utilizing antimicrobial blue light, antimicrobial photodynamic therapy, and germicidal ultraviolet irradiation, among others. Light-based therapy is advantageous over traditional antibiotics in that it eradicates microbial cells rapidly and the likelihood of light-resistance development by microbes is low. Methods This review highlights the patents on light-based therapy that were filed approximately within the last decade and are dedicated to eradicating pathogenic microorganisms. The primary database that was used for the search was Google Patents. The searches were performed using the keywords including blue light, antimicrobial photodynamic therapy, ultraviolet irradiation, antibiotic resistance, disinfection, bacterium, fungus, and virus. Results Forty-five patents were obtained in our search: 9 patents for the antimicrobial blue light approach, 21 for antimicrobial photodynamic therapy, 11 for UV irradiation, and lastly 4 for other light-based anti-infective approaches. The treatments and devices discussed in this review are interestingly enough able to be used in various different functions and settings, such as dental applications, certain eye diseases, skin and hard surface cleansing, decontamination of internal organs (e.g., the stomach), decontamination of apparel and equipment, eradication of pathogenic microorganisms from buildings and rooms, etc. Most of the devices and inventions introduce methods of destroying pathogenic bacteria and fungi without harming human cells and tissues. Conclusions Light-based antimicrobial approaches hold great promise for the future in regards to treating antibiotic-resistant infections and related diseases.

show abstract

Photomanipulation of antibiotic susceptibility and biofilm formation of Escherichia coli heterologously expressing photoactivated adenylyl cyclase

Cited by 8 publications

References 20 publications

Antimicrobial blue light inactivation of pathogenic microbes: State of the art

Antimicrobial blue light inactivation of pathogenic microbes: State of the art

Key Residues for the Light Regulation of the Blue Light-Activated Adenylyl Cyclase from Beggiatoa sp.

Recent Patents on Light-Based Anti-Infective Approaches

Contact Info

Product

Resources

About